Healthcare Industry News: Allergan
News Release - March 10, 2011
Agendia Hires David Macdonald as Chief Operating Officer, Mark Willig as Executive VP of North American Sales, and Doug Bradley as Vice President of Global MarketingIRVINE, California and AMSTERDAM, March 10, 2011 -- (Healthcare Sales & Marketing Network) -- Agendia, a world leader in molecular cancer diagnostics, today announced the hiring of David Macdonald as the company's Chief Operating Officer, Mark Willig as Executive Vice President of North American Sales, and Doug Bradley as Vice President of Global Marketing. Macdonald has been with Agendia for the past eight months in a consulting role and will continue to be responsible for laboratory operations, research and development, product support, information technology and U.S. human resources. Willig brings with him a rich background of executive leadership experience in a variety of commercial roles and will oversee all sales activity in North America. Bradley will manage all strategic and tactical marketing activities.
"As Agendia grows it is vital that we continually seek out the brightest and most innovative minds in the industry to add to our already stellar team," said Dr. Bernhard Sixt, CEO and co-founder of Agendia. "We have done just that with the hiring of David, Mark and Doug, who will help us make more people aware of Agendia's truly revolutionary technology worldwide."
Macdonald has 25 years of experience commercializing clinical diagnostic systems and laboratory services for companies such as Nova Biomedical, Behring Diagnostics, Nichols Institute, Quest Diagnostics, Nanogen, Nanomix and AltheaDx. He has held CEO and COO positions for the past 18 years, and holds a Bachelor of Science degree from Northeastern University in management and finance as well as an MBA from Babson College in marketing and entrepreneurship.
Willig has held a number of senior leadership positions within the healthcare industry, including General Manager and Chief Commercial Officer at Exiqon, VP of Global Sales for Thermo Fisher's $300 million anatomic pathology business unit, Executive Vice President of Sales and Marketing at Specialty Labs, Vice President of Sales at Myriad Genetics, as well as 12 years in commercial roles of increasing responsibility at Abbott Diagnostics. He holds a Bachelor of Science degree from the University of Missouri.
Bradley brings a wealth of leadership experience in medical and pharmaceutical product marketing at companies including Coherent Medical, Allergan and SenoRx. Most recently, he served as Vice President of Marketing at Vertos Medical. In his eight years at Irvine-based SenoRx, Bradley led the company's marketing activities from its infancy. In this role, Bradley became intimately familiar with medical devices for the diagnosis and treatment of breast cancer. During Bradley's time at SenoRx, they received the "Technology Fast 50" award from Deloitte & Touch in 2006, 2007 and 2008. He holds a Bachelor of Science degree in Microbiology from the University of Oklahoma and an MBA from Pepperdine University.
Agendia (http://www.Agendia.com) is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Irvine, California, and in Amsterdam, the Netherlands.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.